Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) — Capital Reinvestment Ratio

Latest as of December 2025: 0.68x

Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has a Capital Reinvestment Ratio of 0.68x as of December 2025, meaning it reinvests 1% of its operating cash flow ($41.05 Million) in capital expenditures ($27.77 Million). Check Zhengye Biotechnology Holding Limited Or tangible book value ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.68x
Capex / Operating Cash Flow

Operating Cash Flow

$41.05 Million
USD

Capital Expenditures

$27.77 Million
USD

Data as of

Dec 2025
Most recent filing

Zhengye Biotechnology Holding Limited Ordinary Shares Capital Reinvestment Ratio (2021–2025)

This chart tracks Zhengye Biotechnology Holding Limited Ordinary Shares's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Zhengye Biotechnology Holding Limited Or.

Annual Capital Reinvestment Ratio for Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)

Year-by-year Capital Reinvestment Ratio for Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025. See Zhengye Biotechnology Holding Limited Or free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.68x $41.05 Million $27.77 Million ▲ +0.0%
2024 0.68x $41.05 Million $27.77 Million ▲ +181.1%
2023 0.24x $48.18 Million $11.60 Million ▼ -84.7%
2022 1.58x $17.34 Million $27.33 Million ▲ +89.9%
2021 0.83x $31.81 Million $26.40 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow